

FORM 7

MONTHLY PROGRESS REPORT

Name of CSE Issuer: **M-Pharmaceutical Inc. ("M-Pharmaceutical")**

Trading Symbol: MQ

Number of Outstanding Listed Securities: **26,291,759**

Date: August 6, 2015

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CSE Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CSE.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CSE Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

M Pharmaceutical Inc. ("the Company") is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous

monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of eMosquito, Trimeo and Trimtec biomedical technologies will require successful coordination and execution of a wide variety of technology disciplines.

On July 7th, the Company announced it's intention to undertake a non-brokered private placement of up to \$350,000. It plans on issuing up to 3,888,888 units at \$0.09 per unit, each unit to consist of one common share and one common share purchase warrant exercisable for one year at \$0.25. Proceeds will be used for general working capital and to further develop the Company's three biomedical technologies.

Please see link here:

http://www.cnsx.ca/cmsAssets/docs/Filings/2015/2015_07_07_19_03_24_MQ_M_P_harmaceutical_Inc_announces_private_placement.pdf

On July 14, 2015, the Company issued 369,200 common shares to PCG Advisory Group. The Common Shares are being issued pursuant to settlement of debt owing by the Corporation to a related party of the Corporation at \$0.12 per Common Share, which has been and continues to provide investor relations and advisory services to the Company.

Please see link here:

http://www.cnsx.ca/cmsAssets/docs/Filings/2015/2015_07_15_9_39_07_MQ_M_Pharmaceutical_Announces_Shares_for_Debt_.pdf

On July 14th, 2015, the Company issued 1,000 common shares for debt at a deemed price of \$0.20.

Please see link here:

http://www.cnsx.ca/cmsAssets/docs/Filings/2015/2015_07_24_12_42_39_MQ_Form_9_Proposed_Issuance_of_Listed_Securities.pdf

On July 16, 2015, the Company announced it's official rebranding. The rebranding is designed to provide greater understanding of the company's emerging family of biomedical technologies. Joining the eMosquito Wearable Blood Monitor will be Trimeo Weight Loss Capsules and the Trimtec Gastric Stimulation System.

Please see link here:

http://www.cnsx.ca/cmsAssets/docs/Filings/2015/2015_07_16_10_16_57_MQ_M_P_harmaceutical_Rebrands_.pdf

On July 17th, 2015, the Company announced highly-touted University of

Calgary gastrointestinal surgeon and diabetes researcher Dr. Oliver Frank Bathe MD, MSc, FRSC(c), FACS, to its board of advisors.

Please see link here:

http://www.cnsx.ca/cmsAssets/docs/Filings/2015/2015_07_17_11_34_58_MQ_M_P_harmaceutical_Inc_has_named_Dr_Oliver_Frank_Bathe_to_its_Advisory_Board.pdf

Provide a general overview and discussion of the activities of management. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Management focused the general development of the company and its three biomedical technologies that make up its newly coined “family of technologies” as noted by the official rebranding. In addition, management focused on adding a strategic member, Dr. Oliver Bathe, to the board of advisors to utilize his experience and knowledge within his respective field that directly relate to technologies the company is currently developing and to assist the company in achieving its near and long-term milestones.

Management officially closed the previously announced acquisition of the Trimtec Gastric Stimulator, making it the third technology in the family of technologies.

2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required on Ontario securities law.

Management completed the previously announced acquisition of the Trimtec Gastric Stimulator.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether

the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer completed the acquisition of the intellectual property associated with the neural gastrointestinal stimulators through the purchase of the Trimtec Biomedical Inc., which allows entry into this market segment.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On July 14, 2015, the Company has issued 1,000 common shares from treasury and assumed the obligations of the exclusive worldwide license agreement covering this technology that Trimtec holds with UTI Limited Partnership at the University of Calgary in Calgary, Alberta.

On July 16, 2015, the Company has issued 369,200 common shares. The Common Shares are being issued pursuant to settlement of debt owing by the Corporation to a related party of the Corporation at \$0.12 per Common Share.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal

parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

M-Pharmaceutical Inc. did not become a party to any legal proceedings during this period.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No indebtedness occurred during this period.

14. Provide details of any securities issued and options or warrants granted.

Not applicable during this period.

15. Provide details of any loans to or by Related Persons.

No loans were made to or by Related Persons during this period.

16. Provide details of any changes in directors, officers or committee members.

The Issuer added Dr. Oliver Bathe to its advisory board.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Not applicable during this period.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: August 7, 2015

Dr. Martin Mintchev, President &
CEO

//Martin Mintchev//

Signature

Director _____
Official Capacity

<i>Issuer Details</i>		
Name of Issuer M-Pharmaceutical Inc.	For Month End July, 2015	Date of Report August 6, 2015
Issuer Address 430-580 Hornby Street		
City/Province/Postal Code Vancouver, B.C. V6C 3B6	Issuer Fax No.	Issuer Fax No. (604) 428 0512
Contact Name Martin Mintchev	Contact Position President & CEO	Contact Telephone No. (604) 428 0511
Contact Email Address info@m-pharma.ca	Web Site Address www.m-pharma.ca	